Insulin is a hormone that supports the body to process glucose from foods to produce energy. It is made in pancreas, the gland present behind the stomach. Most of the people having Type-2 diabetes do not use insulin accurately so they might not make enough insulin to maintain the body’s demands. That is the time they had to start taking insulin.
Without medicine, it is hard to control Type 2 diabetes. People forget or avoid the daily insulin cure due to their busy schedules.
This is soon going to change as researchers have given hope for a new once in a week insulin cure injection that has cleared phase 2 trials as published in The New England Journal of Medicine. The results say that once a week insulin cure is as effective as the regular insulin care and phase 3 trials are on the course.
“This is the first once-a-week injectable insulin, and this study suggests it’s as effective as taking insulin daily. If it does well through scrutiny in phase 3 trials, it could make life easier for people with Type 2 Diabetes,” explained – Dr. Robert Gabbay, chief science and medical officer for the American Diabetes Association.
He also added – “Getting people to start insulin is often a challenge, but if you only have to do it once a week, that may help.”
As people get over the hurdle of regular injections, Gabbay said, they’ll likely “be more adherent, have better blood sugar control and then fewer complications.“
The treatment works by wrapping up with albumin. Wrapping up to albumin keeps it slow and constant. The research took place with 247 people. Two groups were formed. One group was given a placebo weekly one along with the regular daily injections. The other group was provided with real icodec ones and daily placebo doses. The result was found effective in both cases.
Dr Harpreet Bajaj said “We know that many people with type 2 diabetes prefer simplicity, meaning fewer injections and more convenience than what is currently provided with once- or twice-daily basal insulin treatment regimens,”
He also added, “This phase 2 trial demonstrates the potential benefit insulin icodec could offer to people with type 2 diabetes in need of insulin therapy, aiding easy transition onto a new treatment option without the daily burden and complexity that is associated with current therapies and potentially even experience more time in good glycaemic control with low risk of hypoglycaemia.”
Phase 3 research for once a week icodec care is expected to begin later in 2020 by Novo Nordisk. Another research ended inspecting icodec for type-1 diabetes but the conclusion has not yet been announced.